Hematology and Oncology are likely to be among the most dynamic subspecialties of Internal Medicine in the next few decades based on continuing advances in laboratory, clinical, and public health research. The Division of Hematology/Oncology in the Department of Medicine at Columbia prepares its fellows to be creative and productive contributors as researchers and clinicians. Our program provides a broad-based clinical training and rigorous development of a research project with opportunities to work with world-class investigators in an outstanding Ivy League University. Fellows may select options leading to either single or dual board eligibility with either 12 or 18 months, respectively, of direct patient care activity, and an equivalent duration of research training in laboratory, clinical, or public health research. The Division also supports Fellowship Training for Clinician-Scientists enrolled in Clinician-Scientist Training Programs (so-called “Short Track”). Some of the highlights of our program are summarized below.
Our clinical training program features diverse patient care experiences in a dynamic hematology and oncology inpatient, consult, and outpatient environment. Although CUIMC is a referral destination for patients not only in the New York Metropolitan area, but nationally and internationally, it is also a hospital that provides care to an often otherwise underserved population in Upper Manhattan. As a result, fellows manage patients at every stage of disease, from initial diagnostic evaluation to supervision of investigational treatments. Fellows train directly with recognized experts in disease-focused inpatient and outpatient rotations. Fellows are very much the center of our clinical investigation activities, which range from single-institution, investigator-initiated studies to multi-institution protocols sponsored by the Herbert Irving Comprehensive Cancer Center, and cooperative groups such as the Southwest Oncology Group. This research encompasses Phase I, II, and III trials, large populations studies using local and national databases, as well as translational correlative research that leverages Columbia's rich tumor sample bank, clinical database, and access to cutting edge science, such as internationally recognized Columbia Genome Center.
Between first and second years fellows participate in a summer grant-writing workshop that allows each to identify a research mentor and develop a research proposal to obtain research funding such as the the ASCO Young Investigator Award. This experience allows fellows to learn the process of proposal development and grant submission. These projects are then executed during the second and third years. Outside funding is not a requirement, but those who obtain awards may use them to conduct research beyond the third year of clinical fellowship and board eligibility. Fellows may select laboratory research, clinical research, or epidemiology and population science in the Mailman School of Public Health.
The Division is comprised of over 60 faculty members ranging from clinicians to internationally known basic scientists. The faculty's wide-ranging research activities often lead to collaboration with other faculty across the Medical Center.
The clinical activities of the Division are based in the recently remodeled Herbert Irving Pavilion and the 40-inpatient beds on the Hematology Oncology Service of NewYork-Presbyterian Hospital. The research activities of the Division are conducted in the hospital, the Mailman School of Public Health, the Irving Cancer Research Center, and other laboratory buildings throughout the Medical Center campus.
Columbia University is a private Ivy League institution with a national and international reputation for excellence in scholarship. From its founding in 1754, the University has played a significant role in American academic life and its graduates have distinguished themselves in many fields. Columbia is a leading institution in New York, as well as nationally, in terms of number of Nobel laureates, number of Howard Hughes scholars, and ranking in biomedical grants relative to other institutions. Columbia University, College of Physician & Surgeons awarded the first MD degree in North America in 1770.
Conquer Cancer Foundation: Young Investigator Awards
We are pleased to announce the following Hematology and Medical Oncology Fellows received Conquer Cancer Foundation Young Investigator Awards:
2020 Young Investigator Awards
- Dr. Shaheer Khan
- Mentor: Dr. Richard Carvajal
- “JAK1/2 Co-Inhibition in Advanced Solid Organ Transplant-Associated Cutaneous Squamous Cell Carcinoma”
- Dr. Alana Nguyen
- Mentors: Dr. Michael Shen and Dr. Andrea Califano
- “A Reverse-Engineering Approach to Therapy Resistance in Muscle-Invasive Bladder Cancer Using Patient-Derived Organoids”
2019 Young Investigator Awards
- Dr. Rajat Bansal
- Mentor: Dr. Ran Reshef
- "Phase II, single arm, open label study to assess the efficacy of GLP-2 agonist ZP1846 in the prevention of melphalan induced diarrhea among bone marrow transplant patients."
- Dr. Matthew Dallos
- Mentor: Dr. Charles Drake
- "Maximizing androgen deprivation immunogenicity through PD-1 and IL-8 blockade in castration-sensitive prostate cancer."
- Dr. Jessica Hawley
- Mentors: Dr. Charles Drake and Dr. Mark Stein
- "Augmenting the ADT-induced immune infiltrate in metastatic hormone-sensitive prostate cancer with PD-1blockade and docetaxel."
- Dr. Bahar Laderian
- Mentor: Dr. Antonio Fojo and Dr. Susan Bates
- "Toward a better understanding of a rare cancer: studies to explore the etiology and biology of SDHx-associated pheochromocytomas and paragangliomas."
- Dr. Alexander Raufi
- Mentor: Dr. Gulam Manji
- "A phase II study of chemotherapy and immune checkpoint blockade with pembrolizumab in the perioperative and maintenance treatment of locoregional gastric and gastroesophageal junction adenocarcinoma."
- Dr. Vikram Premkumar
- Mentor: Dr. Suzanne Lentzsch
- "Identifying the role of Programmed Death-1 Homolog (PD-1H) on osteocyclast signaling and activation within the bony microenvironment in multiple myeloma bone disease."